P. Libby, Inflammation in atherosclerosis, Nature, vol.103, issue.6917, pp.868-874, 2002.
DOI : 10.1074/jbc.274.45.32048

A. E. May, H. Langer, P. Seizer, B. Bigalke, S. Lindemann et al., Platelet-Leukocyte Interactions in Inflammation and Atherothrombosis, Seminars in Thrombosis and Hemostasis, vol.33, issue.2, pp.123-127, 2007.
DOI : 10.1055/s-2007-969023

D. G. Harrison, T. J. Guzik, H. E. Lob, M. S. Madhur, P. J. Marvar et al., Inflammation, Immunity, and Hypertension, Hypertension, vol.57, issue.2, pp.132-140, 2011.
DOI : 10.1161/HYPERTENSIONAHA.110.163576
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3028593

W. B. Campbell and I. Fleming, Epoxyeicosatrienoic acids and endothelium-dependent responses. Pflugers Arch, pp.881-895, 2010.
DOI : 10.1007/s00424-010-0804-6
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3373596

S. L. Pfister, K. M. Gauthier, and W. Campbell, Vascular Pharmacology of Epoxyeicosatrienoic Acids, Adv. Pharmacol, vol.60, pp.27-59, 2010.
DOI : 10.1016/B978-0-12-385061-4.00002-7
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3373307

G. Patti, D. Grieco, G. Dicuonzo, V. Pasceri, A. Nusca et al., HIGH VERSUS STANDARD CLOPIDOGREL MAINTENANCE DOSE AFTER PERCUTANEOUS CORONARY INTERVENTION AND EFFECTS ON PLATELET INHIBITION, ENDOTHELIAL FUNCTION, AND INFLAMMATION. RESULTS OF THE ARMYDA-150 MG (ANTIPLATELET THERAPY FOR REDUCTION OF MYOCARDIAL DAMAGE DURING ANGIOPLASTY) RANDOMIZED STUDY, Rational Pharmacotherapy in Cardiology, vol.7, issue.5, pp.771-778, 2011.
DOI : 10.20996/1819-6446-2011-7-5-644-652
URL : http://doi.org/10.1016/j.jacc.2010.09.050

S. Sadanandan and I. M. Singh, Clopidogrel, American Journal of Cardiovascular Drugs, vol.71, issue.3, pp.361-374, 2012.
DOI : 10.1067/mcp.2002.122018

K. I. Kalantzi, M. E. Tsoumani, and I. A. Goudevenos, Pharmacodynamic properties of antiplatelet agents: current knowledge and future perspectives, Expert Review of Clinical Pharmacology, vol.366, issue.3, pp.319-336, 2012.
DOI : 10.1056/NEJMoa1200933

M. Singh, B. Thapa, and R. Arora, Clopidogrel Pharmacogenetics and Its Clinical Implications, American Journal of Therapeutics, vol.17, issue.3, pp.66-73, 2010.
DOI : 10.1097/MJT.0b013e3181afbf62

J. Miao, R. Liu, and Z. Li, Cytochrome P-450 polymorphisms and response to clopidogrel, N. Engl. J. Med, vol.360, pp.2250-2251, 2009.

J. S. Hulot, A. Bura, E. Villard, M. Azizi, V. Remones et al., Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects, Blood, vol.108, issue.7, pp.2244-2247, 2006.
DOI : 10.1182/blood-2006-04-013052

P. Fontana, J. S. Hulot, P. De-moerloose, and P. Gaussem, Influence of CYP2C19 and CYP3A4 gene polymorphisms on clopidogrel responsiveness in healthy subjects, Journal of Thrombosis and Haemostasis, vol.5, issue.10, pp.2153-2155, 2007.
DOI : 10.1016/S0140-6736(03)12516-0

A. Bura, C. Bachelot-loza, F. D. Ali, M. Aiach, and P. Gaussem, Role of the P2Y12 gene polymorphism in platelet responsiveness to clopidogrel in healthy subjects, Journal of Thrombosis and Haemostasis, vol.84, issue.9, pp.2096-2097, 2006.
DOI : 10.1161/01.CIR.0000130846.46168.03

S. S. Frøland, A. G. Semb, V. Hansteen, and E. Gjertsen, Clopidogrel increases expression of chemokines in peripheral blood mononuclear cells in patients with coronary artery disease: Results of a double-blind placebo-controlled study, J. Thromb. Haemost, vol.4, pp.2140-2147, 2006.

L. B. Reggiani, L. Alessi, and G. Lauria, A randomised study comparing the antiplatelet and antiinflammatory effect of clopidogrel 150 mg/day versus 75 mg/day in patients with ST-segment elevation acute myocardial infarction and poor responsiveness to clopidogrel: Results from the DOUBLE study, Thromb. Res, vol.125, pp.309-314, 2010.

T. Munzel and A. Warnholtz, Lack of evidence for pleiotropic effects of clopidogrel on endothelial function and inflammation in patients with stable coronary artery disease: Results of the double-blind, randomized CASSANDRA study, Clin. Res. Cardiol, vol.100, pp.29-36, 2011.

S. Husted, R. F. Storey, R. A. Harrington, H. Emanuelsson, and C. P. Cannon, Changes in Inflammatory Biomarkers in Patients Treated With Ticagrelor or Clopidogrel, Clinical Cardiology, vol.20, issue.4, pp.206-212, 2010.
DOI : 10.1161/01.CIR.99.16.2079

M. Woodward, G. D. Lowe, L. M. Francis, A. Rumley, and S. M. Cobbe, A randomized comparison of the effects of aspirin and clopidogrel on thrombotic risk factors and C-reactive protein following myocardial infarction: the CADET trial, Journal of Thrombosis and Haemostasis, vol.345, issue.11, 1934.
DOI : 10.1111/j.1365-2362.1994.tb02373.x

J. B. Muhlestein, Effect of antiplatelet therapy on inflammatory markers in atherothrombotic patients, Thrombosis and Haemostasis, vol.103, issue.1, pp.71-82, 2010.
DOI : 10.1160/TH09-03-0177

C. Bertrand-thiébault, H. Berrahmoune, A. Thompson, B. Marie, S. Droesch et al., Genetic Polymorphism of CYP2C19 Gene in the Stanislas Cohort. A link with Inflammation, Annals of Human Genetics, vol.348, issue.2, pp.178-183, 2008.
DOI : 10.1161/01.CIR.101.15.1767

M. M. Hoffmann, P. Bugert, U. Seelhorst, B. Wellnitz, B. R. Winkelmann et al., The -50G>T Polymorphism in the Promoter of the CYP2J2 Gene in Coronary Heart Disease: The Ludwigshafen Risk and Cardiovascular Health Study, Clinical Chemistry, vol.53, issue.3, pp.539-540, 2007.
DOI : 10.1373/clinchem.2006.084756

D. Kaur-knudsen, S. E. Bojesen, and B. G. Nordestgaard, Common polymorphisms in CYP2C9, subclinical atherosclerosis and risk of ischemic vascular disease in 52???000 individuals, The Pharmacogenomics Journal, vol.271, issue.5, pp.327-332, 2009.
DOI : 10.1161/hh2101.099268

D. J. Angiolillo, Applying Platelet Function Testing in Clinical Practice, JAMA, vol.306, issue.11, pp.1260-1261, 2011.
DOI : 10.1001/jama.2011.1349

R. Hernández, R. Moreno, J. Escaned, and F. Alfonso, Identification of low responders to a 300-mg clopidogrel loading dose in patients undergoing coronary stenting, Thromb. Res, vol.115, pp.101-108, 2005.

P. A. Gurbel, K. P. Bliden, B. L. Hiatt, and C. M. O-'connor, Clopidogrel for Coronary Stenting: Response Variability, Drug Resistance, and the Effect of Pretreatment Platelet Reactivity, Circulation, vol.107, issue.23, pp.2908-2913, 2003.
DOI : 10.1161/01.CIR.0000072771.11429.83

P. A. Gurbel and U. S. Tantry, Drug Insight: clopidogrel nonresponsiveness, Nature Clinical Practice Cardiovascular Medicine, vol.354, issue.7, pp.387-395, 2006.
DOI : 10.1038/ncpcardio0602

I. Muller, F. Besta, C. Schulz, S. Massberg, A. Schonig et al., Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled f or elective coronary stent placement, Thromb. Haemost, vol.89, pp.783-787, 2003.

M. Gawaz, H. Langer, and A. May, Platelets in inflammation and atherogenesis, Journal of Clinical Investigation, vol.115, issue.12, pp.3378-3384, 2005.
DOI : 10.1172/JCI27196

K. Müller, S. Aichele, M. Herkommer, B. Bigalke, K. Stellos et al., Impact of inflammatory markers on platelet inhibition and cardiovascular outcome including stent thrombosis in patients with symptomatic coronary artery disease, Atherosclerosis, vol.213, issue.1, pp.256-262, 2010.
DOI : 10.1016/j.atherosclerosis.2010.07.023

U. Klinkhardt, J. Graff, and S. Harder, Clopidogrel, but not abciximab, reduces platelet leukocyte conjugates and P-selectin expression in a human ex vivo in vitro model, Clinical Pharmacology & Therapeutics, vol.71, issue.3, pp.176-185, 2002.
DOI : 10.1067/mcp.2002.122018

P. Yerino, P. Toren, B. Ogilvie, and A. Parkinson, Unlike Gemfibrozil, Clopidogrel Glucuronide is not a Potent Inhibitior of CYP2C8, Available, vol.online, 2007.

J. S. Hulot, G. Wuerzner, C. Bachelot-loza, M. Azizi, A. Blanchard et al., Effect of an increased clopidogrel maintenance dose or lansoprazole co-administration on the antiplatelet response to clopidogrel in CYP2C19-genotyped healthy subjects, Journal of Thrombosis and Haemostasis, vol.119, issue.3, pp.610-613, 2010.
DOI : 10.1161/CIRCULATIONAHA.108.857722

P. Fontana, A. Dupont, S. Gandrille, C. Bachelot-loza, J. L. Reny et al., Adenosine Diphosphate-Induced Platelet Aggregation Is Associated With P2Y12 Gene Sequence Variations in Healthy Subjects, Circulation, vol.108, issue.8, pp.989-995, 2003.
DOI : 10.1161/01.CIR.0000085073.69189.88
URL : http://circ.ahajournals.org/content/circulationaha/108/8/989.full.pdf